SCHEMBL4222933

SCHEMBL4222933

CCOc1ccccc1NC(=O)Nc1ccc(-c2ccc(C(=O)C3CCCC3C(=O)OC)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 11/20 0.56
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
NPC1 O15118 2/20 0.54
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
RAB9A P51151 2/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
PABPC1 P11940 1/20 0.51
MAPT P10636 2/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222927 1.00 DGAT1 (0.56) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4222925 1.00 DGAT1 (0.56) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4226864 0.91 DGAT1 (0.69) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4226856 0.91 DGAT1 (0.69) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4226860 0.91 DGAT1 (0.69) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4886391 0.80 DGAT1 (0.77) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4890050 0.79 DGAT1 (0.58) DGAT1KMT2AMEN1NPC1RAB9A
SCHEMBL4885534 0.77 DGAT1 (0.84) DGAT1KMT2AMEN1NPC1ALDH1A1
SCHEMBL4230980 0.77 DGAT1 (0.71) DGAT1KMT2AMEN1NPC1LMNA
SCHEMBL4230984 0.77 DGAT1 (0.71) DGAT1KMT2AMEN1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215780-A1 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity FABP4, GPR119, LIPC DGAT1 34/4885KMT2A 627/4885MEN1 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.